Evidence method
Level · gp.fundamentals.debt_to_revenue
226.85% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Jun 30, 2025
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-103120General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.11% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-21.11% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
36.33% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
14.27% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
69.43% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-42.52% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
40.99% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
22.69% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 254.68%
- Current
- 226.85%
- Delta
- -27.83%
- Previous
- 2.40%
- Current
- 1.11%
- Delta
- -1.29%
- Previous
- -54.31%
- Current
- -21.11%
- Delta
- 33.20%
- Previous
- 25.24%
- Current
- 36.33%
- Delta
- 11.08%
- Previous
- 16.56%
- Current
- 14.27%
- Delta
- -2.29%
- Previous
- 67.62%
- Current
- 69.43%
- Delta
- 1.81%
- Previous
- -56.45%
- Current
- -42.52%
- Delta
- 13.93%
- Previous
- 46.15%
- Current
- 40.99%
- Delta
- -5.16%
- Previous
- 23.16%
- Current
- 22.69%
- Delta
- -0.47%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Analogous To · ADPT state analogue 2 →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ADPT CAPEX_INTENSITY_DECREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →Transitioned To · ADPT GROWTH_INCREASED →Transitioned To · ADPT INVENTORY_PRESSURE_DECREASED →Transitioned To · ADPT MARGIN_INCREASED →Transitioned To · ADPT PROFITABILITY_INCREASED →Transitioned To · ADPT R_AND_D_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.